Figure 8

Effects of Saxagliptin on angiogenesis. A) The effect of Saxagliptin on tube formation by HUVECs in 2D Matrigel was assessed. Total tube length as well as average tube length are reported. *p < 0.05 (n = 3 replicates) for Saxagliptin-treated versus the untreated control condition (Ctrl). B) The effect of Saxagliptin on sprouts formation by spheroids of HUVECs was assessed. Total sprouts length as well as the number of sprouts are reported. *p < 0.05 (n = 3 replicates) for Saxagliptin-treated versus the untreated control condition (Ctrl). C) In vivo angiogenesis in Matrigel plugs by PBMCs isolated from Saxagliptin-treated and non-incretinergic drug treated type 2 diabetic patients (n = 5/group). Representative figures, as well as quantification of Hb content are shown. D) PBMC from Saxagliptin-treated and non-incretinergic drug treated type 2 diabetic patients (n = 5/group) were also used for the Directed In Vivo Angiogenesis Assay (DIVAA) using angioreactor tubes with (+) and without (-) growth factors (GF). After visual inspection, Lectin content was determined as an indicator of vascular invasion of the tube. Lectin content quantification in tubes without and with GF, as well as the difference between the two are shown. *p < 0.05 Saxa versus Ctrl.